Among the most intensively studied pathways in lung cancer immunotherapy are the programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) axis and the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) pathway (Cheng et al., 2024). Here, CTLA4 is linked to lung carcinoma.